Feedback / Questions
sabirnetug IV (ACU193 IV) - Acumen Pharma
https://www.globenewswire.com/news-release/2025/12/02/3197864/0/en/Acumen-Pharmaceuticals-Highlights-Enhanced-Brain-Delivery-Technology-for-Oligomer-Selective-Antibodies-and-Recruitment-Strategies-for-Phase-2-ALTITUDE-AD-Clinical-Trial-at-18th-Ann.html
Dec 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next